AstraZeneca's Strategic Move: Licensing Eccogene's Oral GLP-1 for $185M upfront
AstraZeneca has acquired an early-stage oral GLP-1 candidate from Eccogene in a deal worth $185 million upfront. AstraZeneca aims to position this oral alternative as a "best in class" option for type 2 diabetes, weight loss, and other indications, despite trailing behind leaders like Novo Nordisk and Eli Lilly in the GLP-1 market.